Quantcast
Last updated on April 17, 2014 at 11:49 EDT

Latest Heparin Stories

2008-08-22 03:00:10

By Fareed, J Iqbal, O; Cunanan, J; Demir, M; Wahi, R; Clarke, M; Adiguzel, C; Bick, R The conventional management of thrombotic and cardiovascular disorders is based on the use of heparin, oral anticoagulants and aspirin. Despite progress in the sciences, these drugs still remain a challenge and mystery. The development of low molecular weight heparins (LMWHS) and the synthesis of heparinomimetics represent a refined use of heparin. Additional drugs will continue to develop. However, none...

ead188452781564fa99d3c4f9fea7f491
2008-08-18 14:45:00

Larger amounts of fully synthetic heparin could be ready for use in patients in 5 years Robert Linhardt has spent years stitching together minuscule carbohydrates to build a more pure and safer alternative to the commonly used and controversial blood thinner heparin. At the national conference of the American Chemical Society on August 17, 2008, Linhardt announced that his research team may have accomplished this task by building the first fully synthetic heparin. Their creation is the...

2008-08-18 09:01:01

Maximus, a business unit of leading infusion therapy firm Medegen Inc., today announced that as a result of a Co-Marketing Agreement between C.R. Bard and Medegen Inc., the MaxPlus(R) Clear(TM) needleless access connector will now be included in peripherally inserted central catheter (PICC) kits sold by Bard Access Systems. The agreement provides the extra benefits of the MaxPlus Clear product to users of Bard PowerPICC SOLO*, the newly launched PICC designed to provide the efficiency of...

2008-08-14 09:01:14

SAN CARLOS, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced positive results from the Phase 1b proof-of-concept trial of NU172, demonstrating that the direct thrombin inhibitor rapidly produced and maintained anticoagulation with a rapid return toward baseline after the infusion ended with a favorable safety profile. "NU172 has the potential to address many of the limitations of currently available anticoagulants given the profile we have seen to date in preclinical...

2008-08-12 09:01:36

PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has clearance to start human clinical trials in the United States with its anticoagulant reversing agent PMX-60056 under the Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA). PMX-60056 represents an entirely new class of drug, which...

2008-07-31 18:00:49

PolyMedix Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced today that it has completed a registered offering in which it raised a total of $15 million in gross proceeds from the sale of common stock units. The units were priced at $0.70 per unit which at closing separated into a share of PolyMedix common stock and a five year warrant to purchase a share...

a9313bf0d82bc2559dcaabcd3673ec931
2008-07-30 12:15:00

U.S. health officials say they have been able to connect three deaths to a contaminated batch of the blood-thinning drug heparin. A spike in the number of allergic reactions by hospital patients injected with the drug prompted its manufacturer, Baxter International Inc., of suburban Chicago, to pull the heparin from distribution in February. Since then, the U.S. Food and Drug Administration has been examining reports of 93 deaths related to heparin. An FDA scientist told the Chicago Tribune...

2008-07-29 15:00:28

CAMBRIDGE, Mass., July 29, 2008 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today will present safety and tolerability results from a Phase I study of M118, its rationally engineered anticoagulant, in a poster presentation at the IXth World Conference on Clinical Pharmacology and Therapeutics Meeting. The poster, titled "Safety, Tolerability, Pharmacokinetics and...

2008-07-13 15:00:06

By CHRISTOPHER SHERMAN, THE ASSOCIATED PRESS CORPUS CHRISTI, Texas The case of 14 babies who received accidental overdoses while in intensive care has raised new questions about how a common blood-thinning medication could be given to infants repeatedly in the wrong dosage. Unlike a previous case involving Dennis Quaid's twins, the Texas newborns got the overdose because of an error at the hospital pharmacy, not a labeling problem. The actor sued one of heparin's manufacturers last...

2008-07-13 00:00:06

By The Associated Press CORPUS CHRISTI, Texas (AP) - The case of 14 babies who received accidental overdoses while in intensive care has raised new questions about how a common blood-thinning medication could be given to infants repeatedly in the wrong dosage.Unlike a previous case involving twins of actor Dennis Quaid, the Texas newborns got the overdose because of an error at the hospital pharmacy, not a labeling problem.Quaid sued one of heparin's manufacturers last year after his...